Seegene: Q1 2026 Consolidated Revenue KRW 129.1B, Operating Profit KRW 23.6B, Quarterly Dividend KRW 300/Share

Q1 2026 consolidated revenue KRW 129.1B, operating profit KRW 23.6B, net profit KRW 34.7B (parent)
Quarterly dividend of KRW 300 per share (total KRW 13.7B)
R&D expenditure KRW 13.7B, 10.6% of revenue
Continued FDA collaboration and distribution agreement with Bio-Rad in the US
Expanded European IVDR certifications and new product development
Technology-sharing joint ventures with Werfen (Spain) and Hylabs (Israel)
Treasury stock holds 12.77% (6,670,219 shares)
Prior year tax refund error corrected, restating Q1 financial statements